- Letter
- Open access
- Published:
Safety and efficacy of herbal extracts to restore respiratory health and improve innate immunity in COVID-19 positive patients with mild to moderate severity: A structured summary of a study protocol for a randomised controlled trial
Trials volume 21, Article number: 943 (2020)
Abstract
Objectives
Primary Objective
• To assess the efficacy of herbal extracts in boosting innate immunity of patients with COVID-19 infection.
Secondary Objectives
• To assess the efficacy of herbal extracts in restoring respiratory health
• To assess the efficacy of Cap. IP in early recovery of patients and decline in viral load
• To assess the safety of herbal extracts
Trial design
This is a single centre, randomized, 2-arm, parallel group, double blind, 1:1 ratio, controlled, exploratory trial with a study period of 30 days from the day of enrolment.
Participants
Patients attending the COVID treatment centre at Yashwantrao Chavan Memorial Hospital, Nehrunagar, Pimpri, Pune, India were screened for their participation in the study. Patients who were known COVID-19 positive (with positive RT-PCR), eligible and willing were enrolled in the study.
Intervention and comparator
The intervention in the trial has a background in ‘Ayurved’. Intervention Arm: Two capsules, Investigational Product (IP) - 1 - 400mg and Investigational Product - 2 - 450mg, containing herbal extracts (a blend of water and CO2 extracts) of Shunthi (Zingiber officinale (Ginger), Vidanga (Embelia ribes), Yashtimadhu (Glycyrrhiza glabra), Haritaki (Terminalia chebula), Guduchi (Tinospora cordifolia), Shatavari (Asparagus racemosus), Aamalaki (Emblica officinalis), Pippali (Piper longum) and calcined Zinc, Shankha bhasma.
Placebo Arm: Edible starch ~ 450 mg. The look and feel of IP and of Placebo boxes were very similar.
Patients are to take two capsules (one each of IP-1 and IP-2) twice a day for 15 days, and from the 16th day, one capsule of IP-2 twice a day up-to day 30. Capsules are to be administered orally with plain water.
The IP is to be taken with all other concomitant medicines prescribed by the treating physician/doctor.
The dose of each component in the IP is very safe to administer. The investigational products are registered products with the Indian Government and have been used for more than 6 months in various health conditions but not for COVID-19.
Main outcomes
Primary Outcome:
Efficacy of the herbal extracts in COVID 19 positive patients (in declining viral load: time-point: 4 days and early recovery)
Secondary Outcomes:
Efficacy of the herbal extracts as an immune-modulator - TH1, TH2, Th17, IL6, NK Cells and CD markers; Immunoglobulin IGG (Serum); Immunoglobulin IGM (Serum) - at 30 days.
Efficacy of the investigational product in reducing sequela of the disease
Safety analysis (Liver Function Test and Kidney Function Test) including serious allergic reaction of: rash, itching/swelling, severe dizziness, trouble breathing.
Randomisation
An alphanumeric coded set of IP/Placebo containers will be used. Participants will be automatically randomized to two groups in the ratio 1:1.
Blinding (masking)
Participants, caregivers and investigators were blinded.
Numbers to be randomised (sample size)
A total of more than 60 and up to 75 patients were to be enrolled in the study into the two groups, considering drop-outs. 72 were enrolled with 37 into the intervention group and 35 into the placebo group.
Trial Status
Protocol number: CoviQuest-01
Protocol version number: 1.2
Protocol Date: 1st July 2020
The recruitment period is completed for the trial. Date of 1st patient enrolment was 11th Aug 2020 and the last patient was enrolled on 3rd of September 2020.
This is to state that it was a late submission from authors for publication of the protocol to the BMC, after enrolment in the study was over.
Last Participant’s last follow-up is scheduled on 5th October 2020
Trial registration
The trial was prospectively registered with the CTRI (Clinical Trial Registry of India). Registration number is CTRI/2020/07/026570. Registered on 14 July 2020
Full protocol
The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
Availability of data and materials
Data of the participants will be filled in by the study coordinator. Co-PI and PI will have rights to correct the data whenever needed. All the procedures will be carried out by adhering to the Good Clinical Practices (GCP). The monitor will have access to the study documents. The sponsor of the study can audit the study with prior appointment with the PI and the study coordinator.
Acknowledgements
Dr. Bhushan Patwardhan, Vice-Chairman, University Grants Commission, New Delhi, India.
Sr. No. | Name | Affiliation |
1 | Dr. Kalpana Joshi | Dept. of Biotechnology, Sinhagad College of Engineering, Pune |
2 | Dr. Tejas Shah | ACE Hospital & Research Center, Pune |
3 | Dr. Anupama Patankar-Gorde | AMAI Charitable Trust, Pune |
Funding
The study was funded by AMAI Charitable Trust, Pune. The same trust supplied the intervention IP - 1 and IP - 2 and the placebo. The funding body had no role in the design of the study, or in the collection, analysis, interpretation of data or in writing the manuscript.
Author information
Authors and Affiliations
Contributions
SP conceived the study. HR initiated the study design. Final protocol was finalised with inputs from SP, KS and PS. HR and SP provided statistical inputs. All authors contributed to refinement of the study protocol and approved the final manuscript.
Authors’ information
HR and SP possess a background in Ayurved (ancient Indian system of medicine). The intervention in the trial has a background in Ayurved.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
The study is approved by Pimpri Chinchwad Municipal Corporation’s Y.C.M. Hospital Ethics Committee, Pimpri, India on 12 June 2020.
This is to state that appropriate ethical committee approval was taken.
Written consent will be taken from all the eligible and willing participants before their participation in the study.
Consent for publication
Not Applicable.
Competing interests
Dr. Suresh Patankar, who is one of the investigators is associated with the funding agency AMAI Charitable Trust, Pune. All other authors declare that they have no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Additional file 1.
Full Study Protocol.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Rangnekar, H., Patankar, S., Suryawanshi, K. et al. Safety and efficacy of herbal extracts to restore respiratory health and improve innate immunity in COVID-19 positive patients with mild to moderate severity: A structured summary of a study protocol for a randomised controlled trial. Trials 21, 943 (2020). https://doi.org/10.1186/s13063-020-04906-x
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s13063-020-04906-x